Affymax IncOver The Counter Market:AFFY
- LAST PRICE0.0007
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.0007
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AFFY |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Affymax Inc | 26.2K | 0.0x | --- |
Statera Biopharma Inc | 42.9K | 0.0x | --- |
Baudax Bio Inc | 479.5K | 0.0x | --- |
Mymetics Corp | 1.5K | 0.0x | --- |
Acura Pharmaceuticals Inc | 184.8K | -0.1x | --- |
Cannabis Global, Inc. | 2.1K | 0.0x | --- |
Company Information
Affymax, Inc. is a biopharmaceutical company. The Company’s product OMONTYS (peginesatide) is for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells. The Company has a collaboration to develop and commercialize peginesatide with Takeda Pharmaceutical Company Limited. In March 2012, the Food and Drug Administration (FDA) approved the Company’s product, OMONTYS.
Contact Information
- Headquarters
- 600 Fifth Avenue, 2nd FloorNEW YORK, NY, United States 10020
- Phone
- 650-812-8700
- Fax
- 302-645-1280
Executives
- Independent Chairman of the Board
- John Orwin
- President, Chief Executive Officer, Director
- Jonathan Couchman
- Chief Financial Officer
- Mark Thompson
- General Counsel
- Grace Shin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $26.2K |
|---|---|
Revenue (TTM) | $42.0K |
Shares Outstanding | 37.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 6.02 |
EPS | $0.07 |
Book Value | $-0.04 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 0.6 |
Price/Cash Flow (TTM) | 0.0x |
Operating Margin | -13,014.29% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
